Cite
HARVARD Citation
de Kouchkovsky, I. et al. (2021). TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. Journal for immunotherapy of cancer. 9 (5), p. . [Online].